newsfilter
← Latest News
GlobeNewswire·

Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026

  • Helus Pharma will host a webcast on November 16, 2026, at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study for HLP003 in major depressive disorder.
  • The company is developing HLP003, a novel serotonergic agonist that received Breakthrough Therapy Designation from the U.S. FDA for adjunctive treatment of MDD.
  • Helus Pharma is also advancing HLP004, another proprietary NSA, in Phase 2 clinical trials for generalized anxiety disorder.
  • The firm operates in Canada, the United States, the United Kingdom, & Ireland, with an extensive research portfolio of investigational NSAs.
  • Forward-looking statements in the release address plans to present study results, engineer drug discovery platforms, & future regulatory approval timelines, noting risks regarding clinical trial outcomes & financing needs.
  • Investor & media contacts for Helus Pharma include Greg Cavers (CFO) & Matthew Beck (astr partners), while Charlotte Wray (CEO of RXMD) serves as the media contact.
Company
Helus Pharma Inc.
Keywords
Nasdaq:HELP, Helus Pharma Inc.